Minhua Chu, Managing Partner at TransitionValue Partner, shared on X:
“Zelgen Biopharma’s investigational product, ZGGS34 (MUC17/CD3/CD28) injection, has received approval from the FDA for its clinical trial application to treat advanced solid tumors.
ZGGS34 is a trispecific antibody drug developed by the company and its subsidiary, Gensun Biopharma Inc., through its bispecific/multispecific antibody development platform, belonging to the class of trispecific T-cell engager (TriTE) antibody molecules.”
More posts featuring Minhua Chu on OncoDaily.